U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H7NO4
Molecular Weight 169.1348
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NCX-4015

SMILES

OC1=CC(CO[N+]([O-])=O)=CC=C1

InChI

InChIKey=GCKBVYBCFQGKGP-UHFFFAOYSA-N
InChI=1S/C7H7NO4/c9-7-3-1-2-6(4-7)5-12-8(10)11/h1-4,9H,5H2

HIDE SMILES / InChI

Molecular Formula C7H7NO4
Molecular Weight 169.1348
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 10:48:29 GMT 2023
Edited
by admin
on Sat Dec 16 10:48:29 GMT 2023
Record UNII
7KJ5VX45CS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NCX-4015
Common Name English
BENZENEMETHANOL, 3-HYDROXY-, .ALPHA.-NITRATE
Systematic Name English
HBN
Common Name English
3-HYDROXYBENZYL NITRATE
Systematic Name English
(3-HYDROXYPHENYL)METHOXYAZINIC ACID
Systematic Name English
NCX 4015
Code English
Code System Code Type Description
FDA UNII
7KJ5VX45CS
Created by admin on Sat Dec 16 10:48:29 GMT 2023 , Edited by admin on Sat Dec 16 10:48:29 GMT 2023
PRIMARY
CAS
190442-16-1
Created by admin on Sat Dec 16 10:48:29 GMT 2023 , Edited by admin on Sat Dec 16 10:48:29 GMT 2023
PRIMARY
PUBCHEM
11513816
Created by admin on Sat Dec 16 10:48:29 GMT 2023 , Edited by admin on Sat Dec 16 10:48:29 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> METABOLITE
The results relative to i.p. administration show a more pronounced and rapid NO delivery (peak of both NOx and RS-NO at 1 h and plateau between 1 and 2 h), still coincident with the peak of SA, and the presence in plasma of NCX 4015 (a metabolite of NCX 4016 which still bears the nitrate function). In myocardial tissue from p.o. treated rats, no drug or metabolites were ever detected, and the NOx levels were always in the range of the controls.
Related Record Type Details
ACTIVE MOIETY
The results relative to i.p. administration show a more pronounced and rapid NO delivery (peak of both NOx and RS-NO at 1 h and plateau between 1 and 2 h), still coincident with the peak of SA, and the presence in plasma of NCX 4015 (a metabolite of NCX 4016 which still bears the nitrate function). In myocardial tissue from p.o. treated rats, no drug or metabolites were ever detected, and the NOx levels were always in the range of the controls. Conversely, following i.p. treatment, we observed a rapid compartmentalization within the heart of the unchanged drug, which rapidly disappears in favour of its breakdown products NCX 4015 and SA, with a concomitant rise in myocardial NOx levels up to 2 h.
ACTIVE MOIETY
The recent results from in vitro genotoxicity tests on NCX 4015 are not inline either with the results from these earlier tests on NCX 4016 or with an in vivo test suggesting no genotoxicity with NCX 4015, according to the company. The company said it would delay the start of planned Phase II studies of NCX 4016 for Type 2 diabetes pending the completion of additional testing on NCX 4015.
ACTIVE MOIETY
In parallel plasma samples were analyzed by a newly developed LC-MS/MS method for analysis of NCX 4015, the metabolite bearing the nitrate ester function. Using MS/MS with multiple reaction monitoring (MRM) in negative ion mode for NCX 4015 and the internal standard (NCX 4015- 13C-D2) it was possible to detect with sufficient accuracy and precision the metabolite in plasma with a quantification limit of 78.1 ng ml(-1). Concentration versus time profile of plasma NCX 4015 gave a Cmax value of 161.94 +/- 47.4 ng ml(-1) and a tmax 4.5 +/- 1 h. The results indicate that both NOx and RSNO (these last for the first time determined in vivo in man following oral administration of a NO-donor drug) are effective plasma markers of NO release in vivo, the latter being an earlier indicator of NO distribution (tmax 2.0 +/- 0.6 h versus 5.4 +/- 1.2 h).